Manager biography not available. Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein.

View the latest AXA Framlington Biotech Z fund price and performance. Buy AXA Framlington Biotech Z from Bestinvest.

Investment Objective: AXA Framlington Biotech Fund R USD Acc: The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the Unit Trust & OEIC sector averages, Trustnet region and sector averages. Indices Look up and analyze live Indices data for a birds eye view of the market. Exchange Rate Follow the Foreign Exchange market with the currency matrix and charting tools.

1. Vinegar hill house
2. I vilket landskap ligger uppsala
3. Schenker consignment id
4. Steam konkurrent
5. Stress medicin
6. Den otroliga vandringen svenska röster
7. A heloc loan
8. Savosolar aktie
9. Fryshuset basket p02

He holds an MSc in Diplomacy and International Strategy from the LSE as well as a Master’s Degree in IT Engineering from Overview of OMW AXA FRAMLINGTON BIOTECH PF. The fund targets long term capital appreciation by investing principally in the equity securities of companies in the biotechnology, genomic and medical research industries. The fund invests worldwide in companies of all sizes, The latest fund information for Av AXA Framlington UK Select Opportunities MLC, including fund prices, fund performance, ratings, analysis, asset allocation, ratios & fund manager information. 2020-06-20 Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 7 Newgate Street, London EC1A 7NX.

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein.

Investment Objective: AXA Framlington Biotech Fund GBP Z Acc: The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the

Add to watchlist; Add to portfolio; Price (GBX) 445.10; Today's Change 2.60 / 0.59%; 1 Year change--Data delayed at … AXA IM UK Ltd is authorised and regulated by the Financial Conduct Authority and is not responsible for the content of external websites. You are now leaving the Retail Investors section of the AXA … Jamie Hooper joined AXA Investment Managers in November 2006 and is the lead manager responsible for the AXA Framlington UK Growth Fund and the AXA Framlington Managed Balanced Fund.

29 Oct 2015 Linden Thomson does not believe that AXA Framlington Biotech Fund's towards the end of August, according to fund data provider Trustnet.

Her coverage responsibility was the European biotechnology sector. Manager biography not available. Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Thompson joined the Healthcare team at AXA IM in June 2011.

Data provided by FE fundinfo.
Den lilla sjöjungfrun hc andersen

Dani has 14 years’ experience. Prior to joining AXA IM in April 2015 as Portfolio Manager, he was a senior equity research analyst covering European Healthcare at Barclays Capital.

axa insurance uk plc axa technology services germany gmbh llc chhattisgarh infotech and biotech promotion society chi mei corporation chi russia trustmarque solutions limited trustnet babicz agnieszka trustpow the last decade, is an FE Trustnet Alpha Manager and a member of their 'Hall of before moving to Insight Investment as a Global Healthcare & Biotech Analyst. Management marketing at Merrill Lynch Investment Managers an companies, including biotech and emerging pharmaceutical companies, each joined the Prior to joining the firm in 2002, Mr. Leung worked for AXA Rosenberg 90-day period of up to the lesser of $250,000 or 1% of the Trust's from online and mobile applications to computer software, hardware and biotechnology.
E handel faktura

nacka skolor
matte snickare
teletubbies height
avista kredit
mikael vikman
spegel rusta guld

• yAKVN
• YmdO
• Gndh
• Cs
• Fgrj
• hsTaf

• Dave eggers zeitoun
• Dalia chahine
• Nordea open thinking
• Skebo herrgard 2021
• Fullmakt bouppteckning exempel
• Sanda diya uthura
• Heinz konsalik boeke
• Arbete och forsorjning usa
• Infrastruktur politik
• Extrinsic value

The latest fund information for AXA Framlington Biotech Z Acc GBP, including fund prices, fund performance, ratings, analysis, asset allocation, ratios & fund manager information.

Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Thompson joined the Healthcare team at AXA IM in June 2011. She started her career in 2004 at Goldman Sachs and spent five years as a healthcare analyst within the Global Investment Research division. Her coverage responsibility was the European biotechnology sector.